Product Information
RIVASTIGMINE 13.3 MG/24HR PTCH is a generic product labeled by Mylan Pharmaceuticals Inc., priced at $1.8531 per EA under NDC 00378907293. Its NADAC has been published 412 times since Aug 8, 2018.
Strength
13.3 mg/24h
Manufacturer
Mylan Pharmaceuticals Inc.NDC
00378907293
Classification
Generic
Dosage Form
PATCH
Route
TRANSDERMAL
Last Updated
6/17/2026
Active Ingredients
RIVASTIGMINEApproval Type
Generic (ANDA)
FDA Application
ANDA205622On Market Since
6/20/2018
Pharmacological Classes
Price Statistics
The NADAC for RIVASTIGMINE 13.3 MG/24HR PTCH has been published 412 times since Aug 8, 2018, and over the history we have for it it has declined 72.0%. The table below summarizes its recorded NADAC range and movement.
| Current price | $1.8531 per EA |
|---|---|
| All-time high | $7.0523 (Oct 10, 2018) |
| All-time low | $1.6436 (Apr 17, 2024) |
| 52-week high | $2.0633 |
| 52-week low | $1.8531 |
| Median price | $2.8222 |
| Average price | $3.1369 |
| Largest weekly change | -33.3% (Apr 17, 2024) |
| Weeks tracked | 412 |
| Tracking since | Aug 8, 2018 |
Generic Alternatives
The matcher finds 2 NADAC-published products sharing this drug's active ingredient, strength, and dosage form across 2 manufacturers (up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Frequently asked questions
What is the NADAC price of RIVASTIGMINE 13.3 MG/24HR PTCH?
The current National Average Drug Acquisition Cost (NADAC) for RIVASTIGMINE 13.3 MG/24HR PTCH, manufactured by Mylan Pharmaceuticals Inc., is $1.8531 per EA (NDC 00378907293), effective Jun 24, 2026.
How has the price of RIVASTIGMINE 13.3 MG/24HR PTCH changed over time?
Over the history we have for it, the NADAC for RIVASTIGMINE 13.3 MG/24HR PTCH has declined 72.0%. It has been tracked across 412 weekly CMS publications since Aug 8, 2018.
What are the highest and lowest recorded NADAC prices for RIVASTIGMINE 13.3 MG/24HR PTCH?
Since Aug 8, 2018, the NADAC for RIVASTIGMINE 13.3 MG/24HR PTCH has ranged from a low of $1.6436 (Apr 17, 2024) to a high of $7.0523 (Oct 10, 2018), with a median of $2.8222 per EA.
Are there cheaper alternatives to RIVASTIGMINE 13.3 MG/24HR PTCH?
2 NADAC-published products share the same active ingredient, strength, and dosage form as RIVASTIGMINE 13.3 MG/24HR PTCH, but none are currently priced below it.
Who manufactures RIVASTIGMINE 13.3 MG/24HR PTCH?
RIVASTIGMINE 13.3 MG/24HR PTCH (NDC 00378907293) is labeled by Mylan Pharmaceuticals Inc., and CMS classifies it as a generic product.
Related Drugs
Same classification